Hayley R. C. Shanks

Hayley R. C. Shanks

Auto-generated profile, based on publicly available information

Hayley R. C. Shanks

Schulich School of Medicine and Dentistry Western University London Ontario Canada

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 May 2024 in Nature Medicine
Verified
Journal Article
Open access
PDF file
HSHayley R. C. Shanks
Hayley R. C. Shanks
KCKewei Chen
Kewei Chen
EREric M. Reiman
Eric M. Reiman
KBKaj Blennow
Kaj Blennow
JCJeffrey L. Cummings
Jeffrey L. Cummings
TSTaylor W. Schmitz
Taylor W. Schmitz
P75 neurotrophin receptor (p75NTR) signaling pathways substantially overlap with degenerative networks active in Alzheimer disease (AD). Modulation of p75NTR with the first-in-class small molecule LM11A-31 mitigates amyloid-induced and pathological tau-induced synaptic loss in preclinical models. Here we conducted a 26-week randomized, placebo-controlled, double-blinded phase 2a safety and exploratory endpoint trial of LM11A-31 in 242 participants with mild to moderate AD with three arms: placebo, 200 mg LM11A-31 and 400 mg LM11A-31, administered twice daily by oral capsules. This trial met its primary endpoint of safety and tolerability. Within the prespecified secondary and exploratory outcome domains (structural magnetic resonance imaging, fluorodeoxyglucose positron-emission tomography and cerebrospinal fluid biomarkers), significant drug–placebo differences were found, consistent with the hypothesis that LM11A-31 slows progression of pathophysiological features of AD; no significant effect of active treatment was observed on cognitive tests. Together, these results suggest that targeting p75NTR with LM11A-31 warrants further investigation in larger-scale clinical trials of longer duration. EU Clinical Trials registration: 2015-005263-16; ClinicalTrials.gov registration: NCT03069014.

2 November 2022 in Brain Communications
Verified
Journal Article
Open access
PDF file
HSHayley R C Shanks
Hayley R C Shanks
KOKate M Onuska
Kate M Onuska
DBDinesh K Barupal
Dinesh K Barupal
TSTaylor W Schmitz
Taylor W Schmitz
FIFor The Alzheimer’s Disease Neuroimaging Initiative
For The Alzheimer’s Disease Neuroimaging Initiative
TCthe Alzheimer's Disease Metabolomics Consortium
the Alzheimer's Disease Metabolomics Consortium
Basal forebrain cholinergic neurons are among the first cell types affected by Alzheimer’s disease pathology, but the cause of their early vulnerability is unknown. The lipid phosphatidylcholine is an essential component of the cell membrane, and phosphatidylcholine levels have been shown to be abnormal in the blood and brain of Alzheimer’s disease patients. We hypothesized that disease-related changes in phosphatidylcholine metabolism may disproportionately affect basal forebrain cholinergic neurons due to their extremely large size, plasticity in adulthood and unique reliance on phosphatidylcholine for acetylcholine synthesis. To test this hypothesis, we examined whether serum phosphatidylcholine levels predicted longitudinal basal forebrain degeneration in Alzheimer’s disease. All data were collected by the Alzheimer’s Disease Neuroimaging Initiative. Participants were divided into a normal CSF group (controls; n = 77) and an abnormal CSF group (preclinical and clinical Alzheimer’s disease; n = 236) based on their CSF ratios of phosphorylated tau and amyloid beta at baseline. Groups were age-matched (t = 0.89, P > 0.1). Serum lipidomics data collected at baseline were clustered by chemical similarity, and enrichment analyses were used to determine whether serum levels of any lipid clusters differed between the normal and abnormal CSF groups. In a subset of patients with longitudinal structural MRI (normal CSF n = 62, abnormal CSF n = 161), two timepoints of MRI data were used to calculate grey matter annual percent change for each participant. Multivariate partial least squares analyses tested for relationships between neuroimaging and lipidomics data which are moderated by CSF pathology. Our clustering analyses produced 23 serum lipid clusters. Of these clusters, six were altered in the abnormal CSF group, including a cluster of unsaturated phosphatidylcholines. In the subset of participants with longitudinal structural MRI data, a priori nucleus basalis of Meynert partial least squares analyses detected a relationship between unsaturated phosphatidylcholines and degeneration in the nucleus basalis which is moderated by Alzheimer’s disease CSF pathology (P = 0.0008). Whole-brain grey matter partial least squares analyses of all 23 lipid clusters revealed that only unsaturated phosphatidylcholines and unsaturated acylcarnitines exhibited an Alzheimer’s disease-dependent relationship with longitudinal degeneration (P = 0.0022 and P = 0.0018, respectively). Only the unsaturated phosphatidylcholines predicted basal forebrain degeneration in the whole-brain analyses. Overall, this study provides in vivo evidence for a selective relationship between phosphatidylcholine and basal forebrain degeneration in human Alzheimer’s disease, highlighting the importance of phosphatidylcholine to basal forebrain grey matter integrity.

9 May 2019 in Neuropsychopharmacology
Verified
Journal Article
Closed access
PDF file
JLJennifer I. Lissemore
Jennifer I. Lissemore
HSHayley R. C. Shanks
Hayley R. C. Shanks
MBMeryl A. Butters
Meryl A. Butters
ABApoorva Bhandari
Apoorva Bhandari
RZReza Zomorrodi
Reza Zomorrodi
DBDaniel M. Blumberger
Daniel M. Blumberger

10 June 2026 in Alzheimer's & Dementia
Verified
Journal Article
Open access
HSHayley R. C. Shanks
Hayley R. C. Shanks
SCSherry Chen
Sherry Chen
KOKate M. Onuska
Kate M. Onuska
TSTaylor W. Schmitz
Taylor W. Schmitz
The cholinergic neurons of the basal forebrain are among the most vulnerable cell types to age‐ and Alzheimer's disease‐related dysfunction and neurodegeneration. However, the biological bases of basal forebrain cholinergic vulnerability (the why ) and the temporal sequence (the how ) have yet to be fully resolved. In this review, we summarize multi‐disciplinary evidence to present a lifespan staging model of basal forebrain cholinergic vulnerability, which outlines how converging biological stressors position these neurons to fail. We trace the origins of basal forebrain cholinergic vulnerability from evolutionary and neurodevelopmental pressures, which ultimately interact with midlife stressors to culminate in two divergent trajectories of cholinergic aging: resilient and vulnerable. Lastly, we highlight that the branch point in cholinergic aging trajectories may serve as a critical window for intervention if sensitive, specific, and clinically scalable in vivo cholinergic biomarkers can be developed.

28 May 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
KOKate M. Onuska
Kate M. Onuska
HSHayley R.C. Shanks
Hayley R.C. Shanks
LDLauren A. Devito
Lauren A. Devito
QQQi Qi
Qi Qi
ACAlycia M. Crooks
Alycia M. Crooks
TSTaylor W. Schmitz
Taylor W. Schmitz
Synaptic dysfunction is a hallmark of Alzheimer’s disease (AD). Yet due to their plasticity, synapses may also adapt to early AD pathology. Here, we demonstrate that cholinergic neurons mount a presynaptic response to tau pathology in the living human brain. Using multi-tracer positron emission tomography in cognitively normal older adults at risk for AD, we observe that cholinergic neurons increase presynaptic vesicular acetylcholine transporter (VAChT) protein levels when colocalized to tau, but not amyloid. Notably, stronger VAChT responses were associated with cognitive resilience over a decade. Whole-brain single-nucleus RNA sequencing in human and mouse tissue reveal that cholinergic neurons are enriched for a plasticity gene-network anchored to the microtubule-associated protein tau ( MAPT ) gene. In mice, forebrain-specific deletion of VAChT impairs cortical plasticity and hippocampal structural integrity. Overall, our findings identify cholinergic synaptic plasticity, and its failure, as a fundamental mechanism of resilience and vulnerability to tau in presymptomatic AD.